110 related articles for article (PubMed ID: 19243245)
1. Can antibody galactosylation be used to improve radioimmunotherapy of induced peritoneal carcinomatosis of colonic origin in the rat?
Aarts F; Hendriks T; Eek A; Oyen WJ; Bleichrodt RP; Boerman OC
Cancer Biother Radiopharm; 2009 Feb; 24(1):29-34. PubMed ID: 19243245
[TBL] [Abstract][Full Text] [Related]
2. Radioimmunotherapy is an effective adjuvant treatment after cytoreductive surgery of experimental colonic peritoneal carcinomatosis.
Koppe MJ; Hendriks T; Boerman OC; Oyen WJ; Bleichrodt RP
J Nucl Med; 2006 Nov; 47(11):1867-74. PubMed ID: 17079821
[TBL] [Abstract][Full Text] [Related]
3. A comparison between radioimmunotherapy and hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis of colonic origin in rats.
Aarts F; Hendriks T; Boerman OC; Koppe MJ; Oyen WJ; Bleichrodt RP
Ann Surg Oncol; 2007 Nov; 14(11):3274-82. PubMed ID: 17653591
[TBL] [Abstract][Full Text] [Related]
4. The effects of adjuvant experimental radioimmunotherapy and hyperthermic intraperitoneal chemotherapy on intestinal and abdominal healing after cytoreductive surgery for peritoneal carcinomatosis in the rat.
Aarts F; Bleichrodt RP; de Man B; Lomme R; Boerman OC; Hendriks T
Ann Surg Oncol; 2008 Nov; 15(11):3299-307. PubMed ID: 18712445
[TBL] [Abstract][Full Text] [Related]
5. Hyperthermia and fibrinolytic therapy do not improve the beneficial effect of radioimmunotherapy following cytoreductive surgery in rats with peritoneal carcinomatosis of colorectal origin.
Aarts F; Hendriks T; Boerman OC; Oyen WJ; Bleichrodt RP
Cancer Biother Radiopharm; 2008 Jun; 23(3):301-9. PubMed ID: 18593363
[TBL] [Abstract][Full Text] [Related]
6. Timing of adjuvant radioimmunotherapy after cytoreductive surgery in experimental peritoneal carcinomatosis of colorectal origin.
Aarts F; Koppe MJ; Hendriks T; van Eerd JE; Oyen WJ; Boerman OC; Bleichrodt RP
Ann Surg Oncol; 2007 Feb; 14(2):533-40. PubMed ID: 17122992
[TBL] [Abstract][Full Text] [Related]
7. Locoreginal radioimmunotherapy with 186Re-labeled monoclonal antibody in treating small peritoneal carcinomatosis of colon cancer in mice in comparison with 131I-counterpart.
Kinuya S; Yokoyama K; Izumo M; Sorita T; Obata T; Mori H; Shiba K; Watanabe N; Shuke N; Michigishi T; Tonami N
Cancer Lett; 2005 Feb; 219(1):41-8. PubMed ID: 15694663
[TBL] [Abstract][Full Text] [Related]
8. High-dose radioimmunotherapy combined with extracorporeal depletion in a syngeneic rat tumor model: evaluation of toxicity, therapeutic effect, and tumor model.
Mårtensson L; Nilsson R; Ohlsson T; Sjögren HO; Strand SE; Tennvall J
Cancer; 2010 Feb; 116(4 Suppl):1043-52. PubMed ID: 20127949
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy using gemcitabine and radioimmunotherapy in nude mice with small peritoneal metastases of colonic origin.
Koppe MJ; Oyen WJ; Bleichrodt RP; Verhofstad AA; Goldenberg DM; Boerman OC
Cancer Biother Radiopharm; 2006 Oct; 21(5):506-14. PubMed ID: 17105422
[TBL] [Abstract][Full Text] [Related]
10. Optimizing bispecific antibody pretargeting for use in radioimmunotherapy.
Sharkey RM; Karacay H; Richel H; McBride WJ; Rossi EA; Chang K; Yeldell D; Griffiths GL; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3897S-913S. PubMed ID: 14506188
[TBL] [Abstract][Full Text] [Related]
11. Radioimmunotherapy improves survival of rats with microscopic liver metastases of colorectal origin.
de Jong GM; Hendriks T; Eek A; Oyen WJ; Heskamp S; Bleichrodt RP; Boerman OC
Ann Surg Oncol; 2009 Jul; 16(7):2065-73. PubMed ID: 19430843
[TBL] [Abstract][Full Text] [Related]
12. Intraperitoneal radioimmunotherapy to treat the early phase of peritoneal dissemination of human colon cancer cells in a murine model.
Kinuya S; Yokoyama K; Fukuoka M; Hiramatsu T; Mori H; Shiba K; Watanabe N; Shuke N; Michigishi T; Tonami N
Nucl Med Commun; 2007 Feb; 28(2):129-33. PubMed ID: 17198354
[TBL] [Abstract][Full Text] [Related]
13. Radioimmunotherapy prevents local recurrence of colonic cancer in an experimental model.
de Jong GM; Boerman OC; Heskamp S; Aarts F; Bleichrodt RP; Hendriks T
Br J Surg; 2009 Mar; 96(3):314-21. PubMed ID: 19224516
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy using the cyclooxygenase-2 inhibitor Parecoxib and radioimmunotherapy in nude mice with small peritoneal metastases of colonic origin.
Koppe MJ; Oyen WJ; Bleichrodt RP; Hendriks T; Verhofstad AA; Goldenberg DM; Boerman OC
Cancer Immunol Immunother; 2006 Jan; 55(1):47-55. PubMed ID: 15868166
[TBL] [Abstract][Full Text] [Related]
15. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
[TBL] [Abstract][Full Text] [Related]
16. Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region.
Rogers BE; Roberson PL; Shen S; Khazaeli MB; Carpenter M; Yokoyama S; Brechbiel MW; LoBuglio AF; Buchsbaum DJ
Cancer Biother Radiopharm; 2005 Oct; 20(5):502-13. PubMed ID: 16248766
[TBL] [Abstract][Full Text] [Related]
17. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
Koppe MJ; Bleichrodt RP; Soede AC; Verhofstad AA; Goldenberg DM; Oyen WJ; Boerman OC
J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070
[TBL] [Abstract][Full Text] [Related]
18. Intraperitoneal radioimmunotherapy in treating peritoneal carcinomatosis of colon cancer in mice compared with systemic radioimmunotherapy.
Kinuya S; Li XF; Yokoyama K; Mori H; Shiba K; Watanabe N; Shuke N; Bunko H; Michigishi T; Tonami N
Cancer Sci; 2003 Jul; 94(7):650-4. PubMed ID: 12841877
[TBL] [Abstract][Full Text] [Related]
19. Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.
Tijink BM; Neri D; Leemans CR; Budde M; Dinkelborg LM; Stigter-van Walsum M; Zardi L; van Dongen GA
J Nucl Med; 2006 Jul; 47(7):1127-35. PubMed ID: 16818947
[TBL] [Abstract][Full Text] [Related]
20. Trans-cyclooctene tag with improved properties for tumor pretargeting with the diels-alder reaction.
Rossin R; van Duijnhoven SM; Läppchen T; van den Bosch SM; Robillard MS
Mol Pharm; 2014 Sep; 11(9):3090-6. PubMed ID: 25077373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
